Leading global investment banking, securities, and investment management firm Goldman Sachs Group, Inc. offers a broad variety of financial services to a substantial and diverse clientele that consists of corporations, financial institutions, governments, and individuals.
The company was founded in 1869 and has its headquarters in New York, with offices in all of the world’s major financial hubs.
According to the recent corporate shareholdings filed, Goldman Sachs India Limited publicly holds 41 stocks with a net worth of more than Rs. 6,415.3 crore.
The global brokerage firm Goldman Sachs purchased the following Pharma stocks during the March 2024 quarter.
Medplus Health Services Limited
With a market cap of Rs. 8,336 crore, the share price of the company moved up by nearly 3% on the BSE and closed in the green at Rs. 697.2 in the trading session of Tuesday, while its previous closing price was Rs. 677.3.
According to the shareholding pattern data available on the BSE, the global brokerage firm bought a fresh stake in Medplus of about 12.35 lakh equity shares, representing 1.03 percent of the equity stake and has a holding value of Rs. 86.1 crore.
On a year-on-year basis, the company’s revenue from operations grew by nearly 21 percent from Rs. 1,190 crore in Q3 FY22-23 to Rs. 1,441 crore in Q3 FY23-24, accompanied by an increase in the net profit of 7.7 percent, from Rs. 13 crore in Q3 FY22-23 to Rs. 14 crore in Q3 FY23-24.
In the last six months, the stock has delivered negative returns of about 12 percent and nearly 3.81 percent in the last one year. So far in 2024, it has given around 5.94 percent of negative returns.
As of March 2024, FIIs hold 14.94 percent of the shares, whereas DIIs hold 22.47 percent of the shares in the company, aggregating to 37.41 percent of the institutional holdings.
Founded in 2006, Medplus Health Services Limited operates in retail and wholesale sales, manufacturing and contract manufacturing of private label pharmaceutical, wellness and FMCG products, import, distribution, and full-fledged diagnostic centres.
Suven Pharmaceuticals Limited
With a market cap of Rs. 16,751 crore, the share price of the stock moved up by 3.08 percent on BSE to hit an intraday high at Rs. 664.3 in the trading session of Tuesday, compared to its previous closing price of Rs. 644.45.
Goldman Sachs via Goldman Sachs India Equity fund bought a fresh stake in Suven Pharma of about 28.3 lakh equity shares, representing 1.11 percent of the equity stake and has a holding value of Rs. 119.1 crore.
In terms of financials, the company’s revenue from operations declined by nearly 37.8 percent from Rs. 354 crore in Q3 FY22-23 to Rs. 220 crore in Q3 FY23-24, accompanied by a fall in the net profit of 56.5 percent, from Rs. 108 crore in Q3 FY22-23 to Rs. 47 crore in Q3 FY23-24.
In the last six months, the stock has delivered positive returns of about 15.8 percent and nearly 41.4 percent in the last one year. However, so far in 2024, it has given negative returns of around 7.7 percent.
As of March 2024, FIIs hold 9.54 percent of the shares, whereas DIIs hold 17.24 percent of the shares in the company, aggregating to 26.78 percent of the institutional holdings.
Incorporated in 2018, Suven Pharmaceuticals Limited is India’s leading innovator-focused, integrated Pharma & Specialty Chemical CDMO company and specialises in Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and Formulations.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
